Find recruiting clinical trials for NSCLC in the UK — including adenocarcinoma, squamous cell, and large cell subtypes. See your treatment pathway and where trials fit in.
Free to use · Live data from ClinicalTrials.gov · Updated hourly
See where clinical trials fit into your treatment journey
Initial treatment after diagnosis of advanced or metastatic NSCLC
Standard: Chemotherapy + Immunotherapy (e.g. Pembrolizumab + Carboplatin + Pemetrexed)
After progression on 1st-line therapy
Standard: Immunotherapy or Docetaxel ± Ramucirumab
After multiple progressions — clinical trials are especially important here
Standard: Clinical trial enrollment or salvage therapy
Ongoing treatment after initial response
Standard: Pembrolizumab or Pemetrexed maintenance
Non-Small Cell Lung Cancer accounts for about 85% of all lung cancers. Subtypes include adenocarcinoma (most common), squamous cell carcinoma, and large cell carcinoma.
Lung cancer treatment is evolving rapidly. New immunotherapies, targeted therapies, and combination treatments are being tested that may improve outcomes compared to standard care.
Eligibility depends on your specific subtype, stage, biomarker status (PD-L1, EGFR, ALK, KRAS), prior treatments, and overall health. Each trial has specific criteria.
Loading trials from ClinicalTrials.gov...